Lingohr Asset Management GmbH Sells 22,986 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Lingohr Asset Management GmbH reduced its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 71.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,007 shares of the biotechnology company’s stock after selling 22,986 shares during the quarter. Lingohr Asset Management GmbH’s holdings in Exelixis were worth $304,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of EXEL. Allspring Global Investments Holdings LLC increased its stake in Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after purchasing an additional 704,786 shares in the last quarter. Globeflex Capital L P grew its stake in shares of Exelixis by 203.8% in the fourth quarter. Globeflex Capital L P now owns 975,151 shares of the biotechnology company’s stock worth $32,473,000 after acquiring an additional 654,200 shares during the period. Caisse DE Depot ET Placement DU Quebec bought a new stake in shares of Exelixis in the third quarter worth approximately $14,979,000. Raymond James Financial Inc. bought a new stake in shares of Exelixis in the fourth quarter worth approximately $17,046,000. Finally, Burney Co. bought a new stake in shares of Exelixis in the fourth quarter worth approximately $12,267,000. 85.27% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Exelixis

In other news, Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christopher J. Senner sold 29,314 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the completion of the transaction, the chief financial officer now directly owns 779,607 shares in the company, valued at $28,174,996.98. This trade represents a 3.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock valued at $5,177,234 over the last 90 days. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $37.06 on Thursday. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $40.02. The company has a market capitalization of $10.37 billion, a P/E ratio of 20.94, a P/E/G ratio of 1.13 and a beta of 0.57. The firm’s 50 day simple moving average is $35.53 and its two-hundred day simple moving average is $32.71.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, sell-side analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on EXEL shares. Oppenheimer lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. Guggenheim reiterated a “buy” rating and issued a $42.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. BMO Capital Markets lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and lifted their price target for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Exelixis in a research note on Thursday, February 13th. Finally, Bank of America lowered shares of Exelixis from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $35.00 to $39.00 in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.59.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.